12,372 trials
Bardet Biedl Syndrome (BBS) · Alström Syndrome (AS)
Primary: Percentage of Participants (≥12 Years of Age at Baseline) Who Reached ≥10% Weight Loss Threshold After 1 Year (Period 2): Pivotal Cohort — 32.3 percentage of…
Psoriatic Arthritis
Primary: Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI)…
Recurrent Glioblastoma
Primary: Median Overall Survival (OS) — 7.5; 12 months
Presbyopia
Primary: Percentage of Subjects With a ≥ 3-line Gain in BDCVA (Best Distance-Corrected Visual Acuity) at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8, 1 Hour Post-Dose 1…
Presbyopia
Primary: Percentage of Subjects With a ≥ 3-line Gain in BDCVA (Best Distance-Corrected Visual Acuity) at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8, 1 Hour Post-Dose 1…
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Marginal Proportion (Expressed as Percentages) of Participants With Sustained Increase in Hemoglobin Levels From Baseline of ≥ 2 g/dL in the Absence of Red Blood Cell…
Pneumococcal Disease
Primary: Percentage of Participants With Prompted Local Reactions Within 10 Days After Vaccination 1 (20vPnC or 13vPnC) — 12.4; 9.7; 6.2; 4.5 percentage of participants
Hemophilia A
Primary: Change From Baseline in Annualized Number of Bleeding Episodes Irrespective of Exogenous FVIII Replacement Treatment [Annualized Bleeding Rate (ABR) for All Bleeds] in…
Diarrhea, Infantile
Primary: Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5…
HIV Infections
Primary: Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 — 13; 39 Participants — p=0.0005
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 — 7.6; 0.5; 6.2; 0.5 Percentage of participants
Post-acute Covid-19 Syndrome
Primary: Fatigue Assessment Scale (FAS) — 32.9; 31.4; 29.0; 27.4 score on a scale
Tick-Borne Encephalitis
Primary: Percentage of Seropositive Participants at 4 Weeks After Dose 3 — 98.0; 100 Percentage of participants
Parkinson Disease
Primary: Evaluation of Safety and Tolerability Data Collected, Based on Number of Participants With Adverse Events in the LTS Phase — 365 Participants
HIV-1 Infection
Primary: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 — 88.9; 88.3 Percentage of participants